Venus Concept Appoints Dr. Hemanth Varghese as President & Chief Business Officer
October 11 2022 - 7:30AM
Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ:
VERO), a global medical aesthetic technology leader, today
announced the appointment of Dr. Hemanth Varghese to the position
of President & Chief Business Officer, effective October 17,
2022.
“We are delighted to have Hemanth join Venus
Concept at this pivotal time for the Company,” said Rajiv De Silva,
Chief Executive Officer and Director of Venus Concept. “Hemanth is
an accomplished healthcare executive with a 20-year track record of
performance and execution. He is a versatile leader with experience
leading diverse healthcare businesses in high-growth markets in
North America and internationally, managing complex business
transformations and high-growth corporate strategy initiatives,
executing transformational M&A and driving critical business
development activities. I believe Hemanth will bring an important,
complementary skillset to our leadership team as we navigate the
next phase of development for Venus Concept.”
“I am honored to join Rajiv and the leadership
team at Venus Concept at such an important time,” said Dr.
Varghese. “Venus Concept has built a strong brand reputation and
loyal following among aesthetic professionals, with a comprehensive
portfolio of minimally invasive and non-invasive medical aesthetics
technology solutions, an innovative R&D platform and a flexible
commercial model delivering safe and effective aesthetic treatment
options to consumers worldwide. I look forward to working with
Rajiv and the leadership team to drive financial and operational
performance, in order to take the enterprise to the next level and
enhance long-term shareholder value creation.”
Before joining Venus Concept as President and
Chief Business Officer, Dr. Varghese served as Senior Vice
President of Strategy & Operations at HLS Therapeutics from
2017 to 2022. He previously worked for Endo International Plc, a
multinational healthcare company, from 2014 to 2017 as President of
International Pharmaceuticals and Executive Vice President of
Corporate Development & Strategy. From 2009 to 2014, Dr.
Varghese served as General Manager of Vision Care at Bausch &
Lomb and Senior Vice President of Corporate Development at Valeant
Pharmaceuticals (now Bausch Health). He has also held leadership
roles in venture capital and corporate development enterprises with
a specialization in healthcare technology, medical devices and
imaging modalities. Dr. Varghese has an Honors BSc and a PhD in
Medical Biophysics from Western University and is a CFA
charterholder.
About Venus Concept
Venus Concept is an innovative global medical
aesthetic technology leader with a broad product portfolio of
minimally invasive and non-invasive medical aesthetic and hair
restoration technologies and reach in over 60 countries and 18
direct markets. Venus Concept’s product portfolio consists of
aesthetic device platforms, including Venus Versa, Venus Legacy,
Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss,
Venus BlissMAX, Venus Epileve and Venus Viva MD. Venus Concept’s
hair restoration systems include NeoGraft® and the ARTAS® and ARTAS
iX® Robotic Hair Restoration systems. Venus Concept has been backed
by leading healthcare industry growth equity investors including EW
Healthcare Partners (formerly Essex Woodlands), HealthQuest
Capital, Longitude Capital Management, Aperture Venture Partners,
and Masters Special Situations.
Cautionary Statement Regarding
Forward-Looking Statements
This communication contains contains
“forward-looking statements” within the meaning of Section 27A
of the Securities Act of 1933, as amended and Section 21E of
the Securities Exchange Act of 1934, as amended. Any statements
contained herein that are not of historical facts may be deemed to
be forward-looking statements. In some cases, you can identify
these statements by words such as such as “anticipates,”
“believes,” “plans,” “expects,” “projects,” “future,” “intends,”
“may,” “should,” “could,” “estimates,” “predicts,” “potential,”
“continue,” “guidance,” and other similar expressions that are
predictions of or indicate future events and future trends. These
forward-looking statements include, but are not limited to,
statements about our financial performance; the growth in demand
for our systems and other products; and general economic
conditions, including the global economic impact of COVID-19, and
involve risks and uncertainties that may cause results to differ
materially from those set forth in the statements. These
forward-looking statements are based on current expectations,
estimates, forecasts, and projections about our business and the
industry in which the Company operates and management's beliefs and
assumptions and are not guarantees of future performance or
developments and involve known and unknown risks, uncertainties,
and other factors that are in some cases beyond our control. As a
result, any or all of our forward-looking statements in this
communication may turn out to be inaccurate. Factors that could
materially affect our business operations and financial performance
and condition include, but are not limited to, those risks and
uncertainties described under Part II Item 1A—“Risk Factors” in our
Quarterly Reports on Form 10-Q and Part I Item 1A—“Risk Factors” in
our Annual Report on Form 10-K for the fiscal year ended
December 31, 2021. You are urged to consider these factors
carefully in evaluating the forward-looking statements and are
cautioned not to place undue reliance on the forward-looking
statements. The forward-looking statements are based on information
available to us as of the date of this communication. Unless
required by law, the Company does not intend to publicly update or
revise any forward-looking statements to reflect new information or
future events or otherwise.
Investor Relations Contact:
ICR Westwicke on behalf of Venus Concept:
Mike Piccinino, CFA
VenusConceptIR@westwicke.com
Venus Concept (NASDAQ:VERO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Venus Concept (NASDAQ:VERO)
Historical Stock Chart
From Apr 2023 to Apr 2024